“SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”
I read a lot of essays and, believe it or not, I’ve been known to write a few on occasion as well. The majority of them kind of linger in the back of my mind and are slowly forgotten. The ones that stick with me tend to be the application essays that I scrutinize every…
Pimentel et al. evaluated the influence of anti-infliximab antibodies on patients with axial spondyloarthritis. The researchers found that anti-infliximab antibodies were associated with decreased infliximab performance and difficulty tapering its dosage, as well as a good clinical response to a second, alternate tumor necrosis factor inhibitor.
Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.
The story of one patient whose research participation helped establish VEXAS as a diagnosable condition.
It’s an exciting time for ultrasound in rheumatology, & it’s never too late to learn. Whether you’re just starting fellowship or have been practicing for decades, there’s a place for ultrasound in your practice.
Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…
The organization is supporting multiple bills and initiatives to protect and expand rheumatology care in the state.
In an effort to ameliorate serious rheumatology provider shortages, the ACR Workforce Solutions Committee has developed a new resource for primary care providers who treat patients with rheumatic conditions.
Understanding the intersection of diabetes mellitus & rheumatic diseases, including lesser known rheumatic entities of diabetes, such as diabetic cheiroarthropathy, scleredema & diabetic myonecrosis, is crucial for accurate diagnosis.
The newest ICD-10 code set went into effect on Oct. 1 and includes more than 400 new and revised diagnosis codes and headers. In September, the ACR also proposed a new diagnosis code that will undergo a public comment period and consideration for inclusion in a future update.
“He cared when no one else did. He not only took the time to figure out what was wrong but listened to what I had to say no matter how crazy I may have sounded. Dr. Templin is a rare type of doctor—he’s the type that clearly loves his career and patients to the core,”…
Dr. Arthur Grayzel leaves behind a legacy of care as a parent, teacher, researcher & clinician.
Dr. David D’Cruz’s research attempts to help patients make sense of chronic nightmares, an understudied symptom of lupus.
The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.
Dr. May Ching Soh highlighted practical approaches when caring for pregnant patients with rheumatic disease.
A pioneer of pediatric rheumatology in Singapore, Dr. Elizabeth Ang details her unique clinical experiences.
Insights into osteoporosis treatments as societies around the world age.
Can a treat-to-target strategy achieve better outcomes for patients with spondyloarthritis? Insights from the latest data.
Emerging evidence shows COVID-19 infection may have long-term consequences, such as arthritis onset and more.
Symptom checkers, telehealth and more—here are insights into the effects new technologies are having on rheumatology.
Dr. Elizabeth Hazel reflects on her experience as a Canadian swimming competitor in the 1992 Summer Olympics.
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.